Cybin To Co-Sponsor Clinical Trial Testing Psilocybin In Frontline Health Workers With Covid-related Distress

Psychedelics and biotech company Cybin Inc. CYBN CLXPF is co-sponsoring a new clinical trial that will test the benefits of psilocybin treatment in health workers experiencing COVID-related distress.
The randomized, placebo-controlled trial aims to treat symptoms of depression, anxiety, burnout and PTSD among frontline doctors, nurses and healthcare professionals.
Researchers will apply psychedelics-assisted psychotherapy methods that use psilocybin in conjunction with psychological therapy.
Cybin is sponsoring the trial in a partnership with the University of Washington in Seattle.
The organizations want to ascertain whether psychedelic medicine can help clinicians recover from COVID-related distress, said Dr. Alex Belser, Cybin’s chief clinical officer.
“Our nation’s doctors, nurses and clinicians have been shouldering the burden of COVID-19 by taking care of the sickest among us. They’re experiencing high levels of anxiety, depression and burnout. Now it’s our turn to help them,” Belser added.

Cybin CEO, Doug Drysdale, said he is proud to be helping front-line healthcare workers.
"We are also delighted and proud to launch EMBARK, a ground-breaking psychotherapy model aimed at delivering best-practice, supportive healing in conjunction with psychedelic therapeutics.” 

The EMBARK model will be applied to this study for the first time.
Photo by Science in HD on Unsplash

Posted In: PsilocybinCannabisPenny StocksMarkets

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.